Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Prathima, Prakash Rao
- Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route
Abstract Views :296 |
PDF Views:0
Authors
D. Benito Johnson
1,
R. Suresh
1,
Prakash Rao Prathima
1,
R. Venkatnarayanan
1,
P. M. Ashir Ahammad
1
Affiliations
1 Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, IN
1 Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 5, No 1 (2013), Pagination: 51-57Abstract
Toxicity of a substance is nothing but unwanted or series of adverse events that was initiated after administration of particular chemical, physical or biological agent. Acute toxicity study aim is to determine the occurred toxic manifestation of the administered test substance after expose to animals in one or more doses for a period of 14 days. The study provides the information or determination of therapeutic index, i.e. T.I. = LD50/ ED 50. Sub-acute toxicity testing evaluates the toxic effects of drug on repeated exposure and also provides the information on delayed and cumulative effect of the chemicals on the tissues or other biochemical mechanisms Depression is one of the most common psychiatric disorders. The symptoms of depression are often subtle and unrecognized both by patients and by physicians. Major depression remains difficult to treat, despite the wide array of registered antidepressant. Milnacipran is indicated for the treatment of major depressive disorder and management of fibromyalgia. Milnacipran inhibits norepinephrine and serotonin reuptake in a 3:1 ratio, in practical use this means a balanced (equal) action upon both transmitter.Keywords
Milancipran, Depression, Acute Toxicity, Sub-Acute Toxicity
References
- Psychology and the National Institute of Mental Health: A Historical Analysis of Science, Practice, and Policy, Edited by Wade E. Pickren, PhD and Stanley F. Schneider, PhD, American Psychological Association, 2004.
- The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity… Journal of affective disorders, 66(2–3): 2001, 159–64.
- The internal and external validity of the Major Depression Inventory in measuring severity of depressive states... Psychological medicine, 33(2): 2003, 351– 356.
- Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman M, Flory M, Psychiatric Diagnosis in Child and Adolescent Sucide. Archives of general psychiatry, 53(4): 1996, 339-348.
- March J, Silva S, Petrycki S, Curry J, Wells K, Fiarbank J, Burns B, Bomino M, Mcnulty S, Vitiello B, Severe J. Treatment for Adolescent with Depression Study (TADS) Team. Journal of the American Medical Association, 292(7): 2004, 807-820.
- HP Rang, MM Dale, JM Ritter, RJ Flower; RANG and DALE’s Pharmacology. 6thedition. New Delhi: Elsevier; P.557-574, 2007.
- The complete drug reference by Martindale (13th edition) Pharmaceutical press, Page no- 372-375,409, 2005.
- Hussam A. Yacoub, DO, MS, William G. Johnson, MD and Nizar Souayah, MD; Serotonin Syndrome After Administration of Milnacipran For Fibromyalgia; American Academy of Neurology; Neurology 23, 2010, Vol. 74.
- Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. "Biochemical profile of midalcipran (F 2207), 1-phenyl-1- diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug". Neuropharmacology 24 (12): 1985, 1211– 9.
- Briley M, Prost JF, Moret C. "Preclinical pharmacology of Milnacipran". International clinical psychopharmacology 11 Suppl 4: 1996. 9–14.
- R Michael Gendreau, Michael D Thorn, Judy F Gendreau, Jay D Kranzler; Efficacy of Milnacipran in patients with fibromyalgia, The Journal of Rheumatology ;Vol. 32 no. 10 , 2011, 1975-1985.
- Spencer C.M.; Wilde M.I; Milnacipran: A Review of its Use in Depression; Volume 56, Number 3, 1998, Page. 405-427(23).
- Mike Briley; Clinical experience with dual action antidepressants in different chronic pain syndromes; Human Psycho and Experimental Pharmacology; Article first published online: 20 SEP 2004, DOI: 10.1002/hup.621
- Anna M Redmond, John P Kelly, Brian E Leonard, The Determination of the Optimal Dose of Milnacipran in the Olfactory Bulbectomized Rat Model of Depression; Pharmacology Biochemistry and Behavior; Volume 62, Issue 4, April 1999, Pages 619–623.
- S.Neil Vaishnavi, Charles B Nemeroff, Susan J Plott, Srinivas G Rao, Jay Kranzler, Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity; Biological Psychiatry; Volume 55, Issue 3, 1 February 2004, Pages 320–322.